Relative short‐term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1077|33|1|hup.2646-hup.2646

ISSN： 0885-6222

Source： Human Psychopharmacology: Clinical And Experimental (Electronic), Vol.33, Iss.1, 2018-01, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agomelatine for the treatment of major depressive disorder

By Carney Regina M   Shelton Richard C  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2411-2419

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder

By Dubovsky Steven L  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 759-766

Informa Healthcare

Access to resources Recommend Favorite

Agomelatine: a guide to its use in major depressive disorder

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 2, 2010-02 ,pp. : 6-9

Adis International

Access to resources Recommend Favorite

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 30, Iss. 4, 2015-07 ,pp. : 327-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Agomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness

By Kennedy Sidney H.   Rizvi Sakina J.  

CNS Drugs, Vol. 24, Iss. 6, 2010-06 ,pp. : 479-499

Adis International

Access to resources Recommend Favorite